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Artículo de revisión
Hepatitis C
Hugo Mendieta Zerón*
Resumen
 El virus de la hepatitis C (VHC) es el agente etiológico más común,
concomitante con la transfusión sanguínea y con la hepatitis de la
comunidad no-A, no-B, con una seroprevalencia mundial estima-
da de 1%. Este virus RNA se identificó en 1988 y hasta la fecha se
reconocen seis genotipos. La infección por el VHC se vincula con
una plétora de alteraciones inmunológicas y autoinmunitarias. Los
mecanismos propuestos de su patogenicidad son: 1) El VHC es
directamente citotóxico, 2) ocurre una reactividad citotóxica de
células T, 3) el alto promedio de mutaciones en la región hipervariable
del genoma viral (la región Es/NS1), le permite al virus escapar de
la respuesta inmunitaria humeral y celular del huésped, 4) los
monocitos y macrófagos infectados pueden contribuir al daño del
hepatocito. El tratamiento farmacológico actual para la hepatitis C
crónica es una dosis semanal subcutánea de interferón pegilado,
en combinación con una dosis diaria de ribavirina, con una res-
puesta serológica sostenida de cerca del 55% de los pacientes
infectados.
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Abstract
Hepatitis C virus (HCV) is the major etiological agent associated to
blood transfusion and community acquired non-A, non-B hepatitis
with an estimated worldwide seroprevalence of approximately
1%. This RNA virus was identified in 1988; until now six distinct
major genotypes have been identified. HCV infection is associated
with a plethora of immune and autoimmune perturbations. The
proposed mechanisms of the pathogenicity are: 1) HCV is directly
cytotoxic; 2) there is a cytotoxic T cell reactivity to HCV
determinants; 3) the high mutation rate in the hypervariable region
of the viral genome (the Es/NS1 region) allows the virus to escape
the host’s humeral and cellular immune defense, and, 4) monocytes
and macrophages infected with HCV may contribute to the
hepatocyte injury. The current standard pharmacologic treatment
of chronic HCV is weekly subcutaneous peginterferon in
combination with daily oral ribavirin, which results in sustained
virologic response in approximately 55% of chronically infected
patients.
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Etiology
Hepatitis C is an agent that persists in tissue for years by
escaping the immune system, damaging its host while
simultaneously being associated with autoimmune hepati-
tis as well as other putative autoimmune diseases.1 Infection
with hepatitis C virus (HCV) causes chronic hepatitis C
(CHC) in at least 50% of patients.2
HCV is the major etiological agent associated to
transfusion and community acquired non-A, non-B hepati-
tis with an estimated worldwide seroprevalence of
approximately 1%.3 Those at greatest risk for HCV infection
are patients with history of intravenous drug use, and blood
transfusion. Cross-sectional studies report a 1% to 3%
lifetime risk for infection in sexual partners of patients with
known HCV infection. The reported estimated risk for
mother-to-infant transmission of HCV infection has varied
widely, ranging from 0% to 20%. HCV transmission during
normal household events is extremely uncommon.
In 1988 it was identified the linear, single-stranded RNA
virus of the hepatitis C, with positive polarity consisting of
9,400 nucleotides and a single open reading frame that codes
for a viral protein of approximately 3,000 amino acids.4
Although six distinct major genotypes have been identified,
recently numerous sub-species of HCV have been defined
by nucleotide mapping. All are antigenically identical for
the purpose of detection of the disease. The 5´end of the
genome consists of an untranslated highly conserved region
adjacent to the genes for various structural proteins such
as the nucleocapsid core and the viral surface protein. On
the other hand, the envelope proteins are  encoded  for  a
hypervariable region, which varies markedly from viral
isolate to viral isolate and sometimes even within viral agents
isolated from the same patient at different time periods during
the course of infection (quasi-species); this is why no
vaccine against HCV is available.
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Subtypes
HCV is the most variable virus among the hepatitis viruses.
The hypervariable region of the virus genome codes for its
envelope proteins. As a result, these proteins vary from
isolate to isolate and even within the same patient studied
across time.
Genotyping may be clinically important as different
genotypes may have different clinical outcomes in terms of
their disease activity, potential for chronicity, replication
efficiency and response to medical treatment.
In the recently developed consensus system, the various
HCV genotypes have been numbered in the order of their
discovery using Arabic numerals starting with 1a and
extending through 6a. Subtypes within a genotype are
identified by lower-case letters that follow the major type
classification.
Physiopathology
Because HCV-RNA can not integrate into the host’s genome,
it remains a mystery how HCV leads to the development of
hepatocellular carcinoma. HCV is thought to be directly
cytopathic for hepatocytes.
The HCV persists for decades in the infected host. The
injury in most cases of HCV disease is of low grade and
chronic, not severe, fulminating hepatitis due to HCV is
rare.
The role of the immune system in HCV disease is unclear
but we know that immune suppression accelerates the na-
tural history of the disease. Also, we know that HCV
infection is associated with a plethora of immune and
autoimmune perturbations.
It is widely believed that the host’s immune response to
HCV envelope epitopes is the driving force for the numerous
quasi species that exist and enable the virus to persist an
immune response directed against it.
The immune response to HCV may include the
development of rheumatoid factor, antinuclear antibodies
(ANA), anticardiolipin, antithyroid and anti-liver/kidney/
microsomal antibodies (anti-LKM), as well as HCV/anti-HCV
immune complex formation and deposition, cryoglobulins
that may explain the cause of mixed essential cryoglobuline-
mia, and has been associated with membranous and
membranoproliferative glomerulonephritis.5
It has been established that HCV exist in plasma in two
distinct forms: free virus and virus complexed to antibodies.6
The latter form may be neutralized virus. The formation of
neutralizing anti-HCV antibodies might prevent the spread
of infection to neonates from infected mothers.
The proposed mechanisms of the pathogenicity are: 1)
HCV is directly cytotoxic, 2) there is a cytotoxic T cell
reactivity to HCV determinants and may also determine
disease activity or outcome, 3) the high mutation rate in he
hypervariable region of the viral genome (the Es/NS1 region)
allows the virus to escape the host’s humeral and cellular
immune defense, and, 4) monocytes and macrophages
infected with HCV may contribute to the hepatocyte injury
caused by the virus by secreting cytokines that enhance
liver cell injury.
HCV infected plasma cells and persistent HCV infection
facilitate the expression of B cell associated immunologic
processes leading to immunoglobulins production which
have cryoglobulin and rheumatoid factor activity. HCV
infection enhances the expression of HLA antigens on
infected cells, the number of activated T lymphocytes within
infected tissues and the presentation of autoantigens to
both T and B cells.
Histological spectrum extends from normal histology to
extensive inflammation with advanced fibrosis or cirrhosis.
Diagnosis
Out of people with known HCV infection, only 25% to 30%
seek medical attention for symptoms attributable to HCV
infection; however, many of these symptoms, such as fati-
gue, are nonspecific.7 Current methods are not enough to
identify all cases with active HCV infection and these “occult
cases” are detectable only with HCV-RNA testing. HCV can
infect cells other than hepatocytes, such as peripheral
mononuclear cells, pancreatic cells, and salivary glands, as
is the case of HBV.8,9
HCV may elevate liver enzymes only minimally or
transiently, and serum transaminases may be normal in the
setting of histologically proved cirrhosis.10
The detection of HCV-RNA using PCR (polymerase chain
reaction) techniques is the most sensitive method for
detecting HCV currently available. With this technique, HCV-
RNA can be detected within a few days to few weeks of
exposure to HVC, well before the appearance of any form of
anti-HCV, and it persists throughout the duration of the
infection. In chronic HCV infection, the virus may be
detectable only intermittently.
Qualitative and quantitative PCR are possible using
serum and liver tissue. Only at HCV-RNA levels lesser than
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3.5 × 105 genome equivalents/mL of serum the qualitative
assays are useful. A minus strand of RNA is produced from
the RNA with the help of a RNA dependent RNA polymerase.
Most common diagnostic testing relies on identifying
the presence of anti-HCV antibodies in the sera of infected
patients using enzyme immunoassay (EIA) and recombinant
immunoblot assay (RIBA) methodology. The sensitivity of
second-generation HCV EIA appears to be approximately
80 to 90%, although there may be a high level of
nonspecificity (as high as 50%) using confirmatory, second
generation RIBA (RIBA-2) in low-risk populations.
The presence of anti-HCV antibodies by the highly
sensitive and specific RIBA-2 in the presence of elevated
serum transaminase levels is believed to be diagnostic of
HCV infection, although false-positive results are known to
occur. Third-generation EIA and RIBA assays improve
sensitivity slightly, but do not improve specificity
significantly.10,11
Liver biopsy in HCV-infected patients is useful for
gauging disease severity and ruling out other causes of
hepatitis. The characteristic morphological features of HCV
infection include steatosis, lymphoid aggregation within the
portal triads, and infiltration of the interlobular bile ducts
with lymphocytes and plasma cells.12
Despite advances in the detection methods available for
identifying cases of HCV, 5% of patients with chronic liver
disease continue to have cryptogenic disease. Almost a
half of the patients with cryptogenic hepatitis have been
transfused.
Disease
Hepatitis C virus infections become chronic in more than
80% of the patients. CHC infection is a frequent cause of
end stage liver disease and is associated with the
development of both liver cirrhosis and hepatocellular car-
cinoma.
The mean time of development of chronic hepatitis C,
cirrhosis and hepatocellular carcinoma is respectively 10,
21 and 28 years.
A major question is whether or not an association
between autoinmmune hepatitis (AH) and CHC infection
exists.
Patients with CHC have detectable autoantibodies,
specially the liver kidney microsomal (LKM) autoantibody.
Additionally, antinuclear (ANA) and smooth muscle
antibodies occur at higher frequencies.
GOR, which is a naturally occurring pentadecapeptide,
is an epitope that is readily recognizable by the host’s
cellular immune responses and there is a strong relationship
between seropositivity for antibody to GOR and LKM
antobodies and HCV infection.
A structural similarity between the target of these
antibodies and proteins produced by the HCV appears most
likely. As a result, an HCV infection can initiate an immune
response to structurally similar host’s antigens turning them
into auto-antigens.
Treatment
It is essential to determine the precise relationship between
HCV and autoimmunity before starting any treatment
because interferon (IFN)-alpha may precipitate or exacerbate
autoimmune disease symptoms; by the other hand, HCV-
related autoimmune disease has been treated successfully
with corticosteroids, azathioprine, and cyclophosphamide,
although HCV viremia pesists and may worsen.
Essential HCV replication proteins are logical targets for
anti-HCV therapy. A multifunctional enzyme, the NS3 is one
of these putative essential proteins.
With IFN treatment, responders typically experience a
rapid decline in their serum alanine-amino-transferase (ALT)
level, but IFN can produce a deleterious effect in patients
with a coexistent autoimmune disease.
Prospective randomized clinical trials have demonstrated
that both recombinant and lymphoblastoid alpha interferon
were effective in the treatment of chronic hepatitis C.
In a review of 52 randomized clinical trials of chronic
hepatitis C13 interferon (alpha-2a, alpha-2b, alpha-2c and
lymphoblastoid [natural] interferon) initially induced ALT
normalization in 1499/2927 patients (51.2%), but due to a
high relapse rate (>50%), only 482/2218 (21.7%) still had
normal ALT values three months after interferon therapy
had been stopped. The long term response rate significantly
increased with increasing weekly doses and with the
duration of interferon therapy (r=0.25 and 0.38 with p<0.01,
respectively). Correspondingly, the response rate was
correlated most closely with the total dose of interferon
given (r=0.49, p<0.001). The presence of cirrhosis is
associated with markedly reduced short and long-term
response to interferon.
Current therapy for infection with HCV involves treatment
with alpha-interferon, alone or in combination with ribavirin.
Such treatment is only effective for a minority of patients.14
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Therapy with ribavirin leads to diminishment in serum
aminotransferase concentrations in 50 to 60 percent of patients
and, if given for 12 months, to some degree of histological
improvement. Combination therapy of interferon alpha and
ribavirin is most helpful in patients, with a higher rate of
long-term response (40-77%).
A broadly effective antiviral therapy for the treatment of
infections with hepatitis C viruses has yet to be developed.
One of the approaches was the development and design of
specific small molecule drugs to inhibit the proteolytic
processing of the polyprotein.15
Peginterferon in combinations with ribavirin has become
the facto standard of care for treatment of chronic HCV
infection. In subgroup analysis, sustained virologic
response was of 42% in patients infected with genotype 1
and was of 82% in patients infected with genotype 2 or 3.16
Specific cytokines elaborated during HCV infection have
not been thoroughly elucidated, but interleukin-2 (IL-2), IL-
4, IL-10, and interferon-gamma have been reported
significantly elevated in HCV infected patients compared
with normal controls.17
Liver transplantation is a well-accepted, life-saving,
surgical treatment that is available at many different medical
centers.18 It is the only therapeutic option for  the patient
with end-stage liver disease for whom alternative medical
and surgical treatments have been exhausted. Controversies
still exist such as who are the best candidates for a liver
transplant due to differing survival rates and the risk of
recurrent disease.19
Examples of controversial indications include alcoholic
liver disease, viral liver disease, and hepatic cancer.18,19
Liver transplantation needs immune suppression and is
associated with progressive HCV disease. Recurrent
infection can jeopardize the donor liver as a result of a
viral infection and is associated with multiple rejection
episodes.
Many liver transplant recipients with and without overt
clinical (biochemical) hepatitis are viremic. The majority
(>95%) of those who are viremic pre-transplant will be
viremic after transplantation. It is established that HCV
infection most be treated before liver transplant.
The current recurrence rate of hepatitis C virus-related
hepatitis is of 72% at 1 year. The incidence of new acquired
HCV infection is of 20% at 4 years. Liver histology is
essential to identify whether or not post-transplant hepati-
tis is present.
Conclusions
Hepatitis C virus infection is the most frequent cause of
post-transfusion hepatitis and chronic viral hepatitis, which
lead to the development of chronic liver disease, cirrhosis,
and hepatocellular carcinoma. HCV infection is associated
with a broad spectrum of autoimmune diseases, such as
rheumatoid arthritis, lupus erythematosus, thyroiditis,
autoimmune liver disease, etc.
Liver transplantation is the only therapeutic option for
the patient with end-stage liver disease for whom alternative
medical and surgical treatments have been exhausted.
Although it is a well-accepted, life-saving and available at
many different medical centers in the United States, surgical
treatment is not a common procedure in Mexico.
Interferon alpha has successfully reduced viremia/
transaminitis, cryoglobulins, proteinuria and nephritis, but
recurrent disease manifestations are frequent after
discontinuation of therapy.
Current therapy for infection with HCV involves treatment
with alpha-interferon in combination with ribavirin, but a
broadly effective antiviral therapy has yet to be developed.
The current standard of pharmacologic treatment of
chronic HCV is weekly subcutaneous peginterferon in
combination with daily oral ribavirin, which results in
sustained virologic response in approximately 55% of
chronically infected patients. Side effects of interferon
therapy include myalgias, fever, nausea, irritability and
depression.20
Although it is clear that the presence of an antinuclear
antibody does not adversely affect the outcome of interferon
therapy, such patients should be carefully monitored while
receiving interferon for the development of autoimmune
diseases, such as thyroiditis, rheumatoid arthritis, psoriasis,
and systemic lupus erythematosus.21
Given its antiviral response, it is speculated that
interferons and their immunoregulatory effects play major
roles in response to HCV infection. Recently it has been
reported a new drug, the collagen-polyvinylpyrrolidone (clg-
pvp) with immunoregulatory actions;22 these properties
could be a new option for the treatment of HCV infection,
although clinical trials need to be done.
REFERENCES
1. Bayraktar Y, Van Thiel DH, Gurakar A. Hepatitis C and the
controversies it creates relative to liver transplantation and
autoimmune hepatitis. Hepatogastroenterology 1996;43:873-
MENDIETA ZERÓN H
3 5Medicina Interna de México Volumen 19, Núm. 1, enero-febrero, 2003
81.
2. Sherlock DS. Viral hepatitis C. Curr Opin Gastroenterol
1993;9:341-8.
3. Purcell RH. Hepatitis C virus: Historical perspective and current
concepts. FEMS Microbiol Rev 1994;14:181-92.
4. Houghton M, Weiner A, Han J, et al. Molecular biology of the
hepatitis C viruses: Implications for diagnosis, development
and control of viral diseases. Hepatology 1991;14(2):381-8.
5. McMurray RW, Elbourne K. Hepatitis C virus infection and
autoimmunity. Semin Arthritis Rheum 1997;26(4):689-701.
6. Hijikata M, Shimizu Y, Kato H, et al. Equilibrium centrifugation
studies of hepatitis C virus: Evidence for circulating immune
complexes. J Virol 1993;67:1953-8.
7. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes
after transfusion-associated hepatitis C. N Engl J Med
1995;332:1463-6.
8. Muller HM, Pfaff E, Goeser T, et al. Peripheral blood leukocytes
serve as a possible extrahepatic site for hepatitis C virus
replication. J Gen Virol 1993;74: 669-76.
9. Feray C, Zignego AL, Samuel D, et al. Persistent hepatitis B
virus infection of mononuclear blood cells without concomitant
liver infection. Transplantation 1990;49(6):1155-8.
10. Alter HJ. To C or not to C: These are the questions. Blood
1995;85:1681-95.
11. De Medina M, Schiff ER. Hepatitis C: Diagnostic assays. Semin
Liver Dis 1995;15:33-40.
12. Freni MA, Artuso D, Gerken G, et al. Focal lymphocytic
aggregates in chronic hepatitis C: Occurrence, immuno-
histochemical characterization, and relations to markers of
autoimmunity. Hepatology 1995;22:389-94.
13. Niedereu C, Heintges T, Häussinger D. Treatment of chronic
hepatitis C with  alfa-interferon: An analysis of the literature.
Hepatogastroenterology 1996;46:544-56.
14.  Hino K, Sainokami S, Shimoda K, Lino S, Wang Y, Okamoto H,
et al. Genotypes and titers of hepatitis C virus for predicting
response to interferon in patients with chronic hepatitis C. J
Med Virol 1994;42:299-305.
15.  Kwong A. Hepatitis C virus NS3/4A protease. Curr Opin Infec
Dis 1997;10:485-90.
16.  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman
M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial
treatment of chronic hepatitis C: A randomized trial. Lancet
2001;358:958-65.
17. Cacciarelli TV, Martinex OM, Gish RG, et al. Immunoregulatory
cytokines in chronic hepatitis C virus infection: Pre and post-
treatment with interferon alfa. Hepatology 1996;24:6-9.
18. Dienstag. Liver transplantation. Isselbacher KJ, Braunwald
E, Wilson JD, et al, editors. Harrison’s principles of internal
medicine. 13th ed, New York: McGraw-Hill, 1994 vol.
2;pp:1501-4.
19. Van Thiel DH, Carr B, Iwaltsuki S, et al. Liver transplantation
for alcoholic liver disease, viral hepatitis and hepatic
neoplasm. Transplantation Proc 1991;23:1917-21.
20. Herrine SK. Approach to the patient with chronic hepatitis C
virus infection. Ann Intern Med 2002;136(10):747-57.
21. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F,
Francesconi R, et al. Serum autoantibodies in chronic hepa-
titis C: Comparison with autoimmune hepatitis and impact on
the disease profile. Hepatology 1997;26:561-6.
22. Rodríguez-Calderón R, Furuzawa-Carballeda J, Corchado
A, Krötzsch E. Collagen-polyvinylpirrolidone promotes human
wound healing through cytokine downmodulation. Wound
Rep Reg 2001;9(2):166.
HEPATITIS C
